THEVAX GENETICS VACCINE CO., LTD.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
THEVAX GENETICS VACCINE CO., LTD.’s "PEK fusion protein technology" is an immunotherapy specifically designed to induce a "cellular immune response." This is an immune response capable of effectively clearing infected or cancerous cells in patients. Targeting different diseases, simply by inserting different antigens into the "PEK fusion protein," it has the potential to become a promising new drug for treating specific diseases. Therefore, the application potential of PEK technology is extremely broad. The first adopter was Reber Genetics, the animal health company of the Sheng Bao Group. Reber Genetics inserted antigens related to Porcine Reproductive and Respiratory Syndrome (PRRS, or blue-ear pig disease) into the PEK fusion protein, creating the PRRSFREE vaccine. This vaccine has already been launched and sold in several countries, validating the feasibility of the PEK technology concept. THEVAX GENETICS VACCINE CO., LTD. has introduced this technology into the field of human disease treatment. To treat conditions including cervical precancerous lesions, relevant antigens were inserted into the PEK fusion protein, leading to the development of the TVGV-1 therapy.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2012
Unified Business No.
53778660
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,028,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
THEVAX GENETICS VACCINE CO., LTD. is a subsidiary of HealthBanks Cord Blood Group. Established in 2012, the company focuses on immunotherapies for cancer, precancerous lesions, and infectious diseases. Currently, THEVAX GENETICS VACCINE CO., LTD. utilizes the group's two major patented vaccine technology platforms, "Reverse Genetic Engineering Technology" and "Target Cell-Specific Fusion Antigen." Based on the Pseudomonas aeruginosa exotoxin fusion protein vaccine platform technology, the cervical cancer vaccine TVGV-1 developed by the company completed Phase I human clinical trials in the United States in 2014.
(The content above was translated by AI.)
(The content above was translated by AI.)
